# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

> **NCT05006794** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 145 (estimated)

## Conditions studied

- Solid Malignancies

## Interventions

- **DRUG:** zamzetoclax
- **DRUG:** Docetaxel
- **DRUG:** sacituzumab govitecan-hziy

## Key facts

- **NCT ID:** NCT05006794
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-15
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05006794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05006794, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05006794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*